Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

MyNCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1997 1
1998 5
1999 16
2000 16
2001 18
2002 24
2003 25
2004 23
2005 22
2006 26
2007 35
2008 27
2009 26
2010 28
2011 18
2012 18
2013 27
2014 20
2015 13
2016 11
2017 16
2018 13
2019 6
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

392 results
Results by year
Filters applied: . Clear all
Page 1
Cysteinyl-leukotriene pathway as a new therapeutic target for the treatment of atherosclerosis related to obstructive sleep apnea syndrome.
Gautier-Veyret E, Bäck M, Arnaud C, Belaïdi E, Tamisier R, Lévy P, Arnol N, Perrin M, Pépin JL, Stanke-Labesque F. Gautier-Veyret E, et al. Pharmacol Res. 2018 Aug;134:311-319. doi: 10.1016/j.phrs.2018.06.014. Epub 2018 Jun 18. Pharmacol Res. 2018. PMID: 29920371
Aspirin exacerbated respiratory disease: Current topics and trends.
Rodríguez-Jiménez JC, Moreno-Paz FJ, Terán LM, Guaní-Guerra E. Rodríguez-Jiménez JC, et al. Respir Med. 2018 Feb;135:62-75. doi: 10.1016/j.rmed.2018.01.002. Epub 2018 Jan 10. Respir Med. 2018. PMID: 29414455 Free article. Review.
Omalizumab reduces cysteinyl leukotriene and 9α,11β-prostaglandin F2 overproduction in aspirin-exacerbated respiratory disease.
Hayashi H, Mitsui C, Nakatani E, Fukutomi Y, Kajiwara K, Watai K, Sekiya K, Tsuburai T, Akiyama K, Hasegawa Y, Taniguchi M. Hayashi H, et al. J Allergy Clin Immunol. 2016 May;137(5):1585-1587.e4. doi: 10.1016/j.jaci.2015.09.034. Epub 2015 Nov 11. J Allergy Clin Immunol. 2016. PMID: 26559322 Clinical Trial. No abstract available.
392 results
Jump to page
Feedback